Promising candidates from drug clinical trials: Implications for clinical treatment of Alzheimer's disease in China
Alzheimer's disease is the most common neurodegenerative disease. Prior to 2017, National Medical Products Administration approved only four drugs to treat Alzheimer's disease, including three cholinesterase inhibitors and one N-methyl-D-aspartate receptor antagonist. We queried ClinicalTr...
Main Authors: | Yuxia Cao, Feng Yu, Yi Lyu, Xianfu Lu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-11-01
|
Series: | Frontiers in Neurology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fneur.2022.1034243/full |
Similar Items
-
An online survey on public awareness of drug clinical trials in inland cities of northern China
by: Li Wang, et al.
Published: (2024-04-01) -
Clinical Trial Design in Alzheimer's Disease
by: Seyed Mehrdad Savar, et al.
Published: (2022-06-01) -
Analysis of the progress of clinical trials for ophthalmic drug in China, 2022
by: Jian-Ping Hu, et al.
Published: (2023-07-01) -
The changing landscape of drug clinical trials on cardiometabolic diseases in China, 2009–2021
by: Chen Li, et al.
Published: (2023-04-01) -
Estimating attrition in mild-to-moderate Alzheimer’s disease and mild cognitive impairment clinical trials
by: Marina Ritchie, et al.
Published: (2023-11-01)